These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11239376)

  • 21. Long-term nifekalant use in a patient with dilated cardiomyopathy and recurrent ventricular tachycardia.
    Xiao H; Chen Q; Tao L
    J Int Med Res; 2022 Oct; 50(10):3000605221133704. PubMed ID: 36300319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Nifekalant hydrochloride effective against perioperative ventricular tachycardia in patients with impaired left ventricular function].
    Murakami T; Makino Y; Kato H
    Kyobu Geka; 2007 Jun; 60(6):469-73. PubMed ID: 17564063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach.
    Sahara M; Sagara K; Yamashita T; Iinuma H; Fu LT; Watanabe H
    Circ J; 2003 Aug; 67(8):712-4. PubMed ID: 12890916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophysiological, rate dependent, and autonomic effects of the class III antiarrhythmic almokalant after myocardial infarction in the pig.
    Tuininga YS; De Langen CD; Crijns HJ; Wiesfeld AC; Mook PH; Bel KJ; Lie KI
    Pacing Clin Electrophysiol; 1996 May; 19(5):802-10. PubMed ID: 8734747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The efficiency of nifekalant hydrochloride for the prevention of ventricular tachycardia during cardiac surgery].
    Sakaguchi M; Takemura T; Shimamura Y; Tsuda Y; Iwasa S
    Kyobu Geka; 2004 Mar; 57(3):191-5. PubMed ID: 15035072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nifekalant hydrochloride administration during cardiopulmonary resuscitation improves the transmural dispersion of myocardial repolarization: experimental study in a canine model of cardiopulmonary arrest.
    Yoshioka K; Amino M; Usui K; Sugimoto A; Matsuzaki A; Kohzuma K; Kanda S; Deguchi Y; Ikari Y; Kodama I; Tanabe T
    Circ J; 2006 Sep; 70(9):1200-7. PubMed ID: 16936437
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of nifekalant for acute conversion of atrial flutter: the possible termination mechanism of typical atrial flutter.
    Morita N; Tanaka K; Yodogawa K; Hayashi M; Akutsu K; Yamamoto T; Satoh N; Kobayashi Y; Katoh T; Takano T
    Pacing Clin Electrophysiol; 2007 Oct; 30(10):1242-53. PubMed ID: 17897127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nifekalant versus lidocaine for in-hospital shock-resistant ventricular fibrillation or tachycardia.
    Shiga T; Tanaka K; Kato R; Amino M; Matsudo Y; Honda T; Sagara K; Takahashi A; Katoh T; Urashima M; Ogawa S; Takano T; Kasanuki H;
    Resuscitation; 2010 Jan; 81(1):47-52. PubMed ID: 19913983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electrophysiological mechanisms of action of ethmozine that explain its antiarrhythmic efficacy in the late stage of experimental myocardial infarction in dogs.
    Aidonidis I; Egel E; Hilbel T; Rizos I; Kuebler W; Brachmann J
    Eur Heart J; 1994 Dec; 15(12):1698-704. PubMed ID: 7698141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of pure potassium channel blocker nifekalant and sodium channel blocker mexiletine on malignant ventricular tachyarrhythmias.
    Otuki S; Hasegawa K; Watanabe H; Katsuumi G; Yagihara N; Iijima K; Sato A; Izumi D; Furushima H; Chinushi M; Aizawa Y; Minamino T
    J Electrocardiol; 2017; 50(3):277-281. PubMed ID: 28238302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Magnesium: current studies--critical evaluation--consequences].
    Meinertz T
    Z Kardiol; 1996; 85 Suppl 6():147-51. PubMed ID: 9064959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nifekalant hydrochloride for patients with cardiac arrest caused by shockable rhythm.
    Nagao K
    Circ J; 2010 Nov; 74(11):2285-7. PubMed ID: 20962421
    [No Abstract]   [Full Text] [Related]  

  • 34. Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties.
    Mizobuchi M; Enjoji Y; Yamamoto R; Ono T; Funatsu A; Kambayashi D; Kobayashi T; Nakamura S
    Pacing Clin Electrophysiol; 2008 Sep; 31(9):1229-32. PubMed ID: 18834480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacological and clinical profile of nifekalant (shinbit injection), a class III antiarrhythmic drug].
    Oyabe A; Sano H
    Nihon Yakurigaku Zasshi; 2002 Feb; 119(2):103-9. PubMed ID: 11862758
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electrocardiographic correlates of spontaneous termination of ventricular tachycardia in patients with coronary artery disease.
    Duff HJ; Mitchell LB; Gillis AM; Sheldon RS; Chudleigh L; Cassidy P; Chiamvimonvat N; Wyse DG
    Circulation; 1993 Sep; 88(3):1054-62. PubMed ID: 8353867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment for perioperative arrhythmias with nifekalant hydrochloride].
    Nishida M; Okada H; Murakami M; Hamano K
    Kyobu Geka; 2006 Mar; 59(3):210-3. PubMed ID: 16528993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Nifekalant hydrochloride as an effective treatment for postoperative ischemic heart disease].
    Enomoto Y; Aoki K; Toshimitsu Y; Inai Y; Asakura T; Furuta S
    Kyobu Geka; 2005 Apr; 58(4):316-9. PubMed ID: 15828253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group.
    Bashir Y; Thomsen PE; Kingma JH; Møller M; Wong C; Cobbe SM; Jordaens L; Campbell RW; Rasmussen HS; Camm AJ
    Am J Cardiol; 1995 Nov; 76(14):1040-4. PubMed ID: 7484858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent.
    Isomoto S; Konoe A; Centurion OA; Hayano M; Kaibara M; Hirata T; Yano K
    Pacing Clin Electrophysiol; 1995 Nov; 18(11):2022-7. PubMed ID: 8552516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.